Page 51 - ATHM26_4

53. Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L. Administration of
reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: Effect
on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Anticancer Drug. 2009;20(5):396-402.
54. Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and
improves quality of life of women diagnosed with ovarian cancer treated with
cisplatin: Results of a double-blind, randomized trial. Ann Oncol. 1997;8(6):569-
573.
55. Leal AD, Qin R, Atherton PJ, et al. North Central Cancer Treatment Group/
Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/
carboplatin-induced peripheral neuropathy: A phase 3 randomized, double-blind,
placebo-controlled study. Cancer. 2014;120(12):1890-1897.
56. Silva RV, Oliveira JT, Santos BLR, et al. Long-chain omega-3 fatty acids
supplementation accelerates nerve regeneration and prevents neuropathic pain
behavior in mice. Front Pharmacol. 2017;8:723.
57. Shapiro H. Could n-3 polyunsaturated fatty acids reduce pathological pain by
direct actions on the nervous system? Prostaglandins Leukot Essent Fatty Acid.
2003;68(3):219-224.
58. Mazza M, Pomponi M, Janiri L, Bria P, Mazza S. Omega-3 fatty acids and
antioxidants in neurological and psychiatric diseases: An overview. Prog
Neuropsychopharmacol Biol Psychiatry. 2007;31(1):12-26.
59. Ghoreishi Z, Esfahani A, Djazayeri A, et al. Omega-3 fatty acids are protective
against paclitaxel-induced peripheral neuropathy: a randomized double-blind
placebo controlled trial. BMC Cancer. 2012;12:355.
60. Anoushirvani AA, Poorsaadat L, Aghabozorgi R, Kasravi M. Comparison of the
effects of omega 3 and vitamin e on palcitaxel-induced peripheral neuropathy.
Open Access Maced J Med Sci. 2018;6(10):1857-1861.
61. Laires MJ, Monteiro CP, Bicho M. Role of cellular magnesium in health and
human disease. Front Biosci. 2004;9:262-276.
62. Hoenderop JG, Bindels RJ. Epithelial Ca2+ and Mg2+ channels in health and
disease. J Am Soc Nephrol. 2005;16(1):15-26.
63. Bara M, Guiet-Bara A, Durlach J. Regulation of sodium and potassium pathways
by magnesium in cell membranes. Magnes Res.1993;6(2):167-177.
64. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis
of oxaliplatin neurotoxicity: Current management and development of preventive
measures. Semin Oncol. 2002;29(suppl 15):21-33.
65. Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A
comprehensive survey. Cancer Treat Rev. 2014;40(7):872-882.
66. Vincenzi B, Frezza AM, Schiavon G, et al. Identification of clinical predictive
factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer
patients treated with adjuvant Folfox IV. Support Care Cancer. 2013;21(5):1313-
1319.
67. Wesselink E, Winkels RM, van Baar H, et al. dietary intake of magnesium or
calcium and chemotherapy-induced peripheral neuropathy in colorectal cancer
patients. Nutrients. 2018;10(4): pii:E398.
68. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related
neurotoxicity by calcium and magnesium infusions: A retrospective study of 161
patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for
advanced colorectal cancer. Clin Cancer Res. 2004;10(12 Pt 1):4055-4061.
69. Grothey A, Nikcevich DA, Sloan JA, et al. Intravenous calcium and magnesium
for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG
N04C7. J Clin Oncol. 2011;29(4):421-427.
70. Hochster HS, Grothey A, Hart L, et al. Improved time to treatment failure with an
intermittent oxaliplatin strategy: Results of CONcePT. Ann Oncol. 2014;25(6):1172-
1178.
71. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, et al. Phase III randomized,
placebo-controlled, double-blind study of intravenous calcium and magnesium to
prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin
Oncol. 2014;32(10):997-1005.
72. Boyette-Davis JA, Walters ET, Dougherty PM. Mechanisms involved in the
development of chemotherapy-induced neuropathy. Pain Manag. 2015;5(4):285-
296.
73. Schloss J, Colosimo M, Vitetta L. New insights into potential prevention and
management options for chemotherapy-induced peripheral neuropathy. Asia Pac
J Oncol Nurs. 2016;3(1):73-85.
74. Wu BY, Liu CT, Su YL, Chen SY, Chen YH, Tsai MY. A review of complementary
therapies with medicinal plants for chemotherapy-induced peripheral neuropathy.
Complement Ther Med. 2019;42:226-232.
75. Sørensen JM. Herb-drug, food-drug, nutrient-drug, and drug-drug interactions:
Mechanisms involved and their medical implications. J Altern Complement Med.
2002;8(3):293-308.
76. Fu B, Wang N, Tan HY, Li S, Cheung F, Feng Y. Multi-component herbal products
in the prevention and treatment of chemotherapy-associated toxicity and side
Effects: A review on experimental and clinical evidences. Front Pharmacol.
2018;9:1394.

Liu—Complementary Nutritional Supplements and Chemotherapy-induced ALTERNATIVE THERAPIES, JUL/AUG 2020 VOL. 26 NO. 4 49